Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ifinatamab deruxtecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ifinatamab deruxtecan overview
Ifinatamab deruxtecan (DS-7300) is under development for the treatment of solid tumors including advanced or metastatic head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, squamous and adenocarcinoma of non-small cell lung cancer (NSCLC), small-cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer and breast cancer.
It is also under development for pretreated extensive-stage small cell lung cancer (ES-SCLC). It targets B7-H3/CD276 antigen. The drug candidate is based on antibody drug conjugate (ADC) technology. It is administered through intravenous route as a solution. The drug candidate comprises of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker.
Daiichi Sankyo overview
Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
For a complete picture of Ifinatamab deruxtecan’s drug-specific PTSR and LoA scores, buy the report here.